CRO-LRI launches new Business Development platform for GLP certification

LAB Research launches new Business Development platform following the recent GLP recertification of its two European sites and signs up exclusive agent for Japan LAB Research Inc. ("LRI" or "LAB Research"), a Canadian-based global non-clinical contract research organization ("CRO"), announces the implementation of a new Business Development platform (the "BD Platform") in Europe to leverage the recent Good Laboratory Practices ("GLP") recertification of both the Hungarian ("LAB Hungary") and Danish sites, as well as the recent expansion of these two European laboratories. LAB Research also announced that it entered into an exclusive agency agreement with Media Services, a Japan-based consulting company. Under the terms of the agreement, Media Services will represent LAB Research in Japan by targeting the large Japanese pharmaceutical market, as well as assist LAB Hungary in better serving the local agro-chemical market.

After the successful GLP recertification of the Hungarian laboratories announced October 23rd, 2008, LAB Research's Danish site has also successfully completed its biennial GLP inspection by the Danish Medicines Agency ("DMA") on October 31, 2008.

The new BD Platform coupled with the Media Services agreement is intended to significantly enhance the marketing of the sites' respective capabilities as well as facilitate cross-selling between the LAB Research entities. These initiatives follow the recent hiring of several new business development veterans joining LAB Research directly from CROs such as Taconic (Europe),Sequani (UK) and RCC/Safepharm Laboratories (Europe), with more than 50 years of combined CRO experience.

"We are proud to have attracted such quality CRO veterans to LRI to join our expanding European operations and we expect this new BD Platform to have an immediate impact on the sites' respective performance. The recent industry trends and market conditions favor laboratories that can compete on quality, scheduling and price, all of which have been facilitated by the recent GLP recertification and the 2007 expansion of our two European sites" mentioned Mr. Mainville, President and CEO of LAB Research.

Media Services, one of the most reputable CRO consulting firms in Japan, will be assisting LAB Research in better serving the local Japanese pharmaceutical market. Media Services was, until recently, representing one of Europe's largest CRO in Japan. LAB Research expects that by partnering with an established organization such as Media Services, it will rapidly increase its profile within the Japanese market. So far, although the agreement is in its infancy, LAB Hungary has already secured more contract signings from that territory than during the previous 2 year period.

"The Japanese market requires a dedicated business development approach and Media Services will provide just that. Their understanding and knowledge of the local Japanese market will accelerate our efforts to gain market share in this large but competitive market" stated Chris Banks, Site Manager of LAB Research Hungary. "We are also excited about the fact that Media Services has agreed to partner with Masahiro Iwasaki, who has previously represented one of the world's largest CROs in Japan. This addition will be a tremendous benefit to LAB Research in our attempt to better serve the local pharmaceutical market. The early benefits of the agreement with Media Services are already tangible and we are excited about the opportunities for the future as we focus on making each of LAB Research's sites successful" added Mr. Banks.

ABOUT LAB RESEARCH INC.
LAB Research is a Canadian global non-clinical contract research
organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary. LAB Research's shares trade on the TSX under the symbol "LRI", with 18.1 million shares outstanding.